Takeda Pharmaceutical (NYSE:TAK) Insider Awny Samaan Botros Farajallah Sells 14,006 Shares

Takeda Pharmaceutical Co. (NYSE:TAK) insider Awny Samaan Botros Farajallah sold 14,006 shares of Takeda Pharmaceutical stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $239,502.60. Following the completion of the sale, the insider directly owned 116,177 shares in the company, valued at approximately $1,986,626.70. This represents a 10.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Price Performance

Shares of TAK opened at $17.42 on Thursday. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. Takeda Pharmaceutical Co. has a twelve month low of $12.99 and a twelve month high of $18.90. The stock has a market capitalization of $55.82 billion, a P/E ratio of 51.24 and a beta of -0.08. The company has a 50 day moving average of $16.49 and a 200-day moving average of $17.13.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The business had revenue of $6.90 billion for the quarter. As a group, equities research analysts forecast that Takeda Pharmaceutical Co. will post 3.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on TAK shares. Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Finally, Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Hedge Funds Weigh In On Takeda Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in TAK. Valeo Financial Advisors LLC acquired a new position in Takeda Pharmaceutical during the second quarter worth $163,000. GAMMA Investing LLC lifted its stake in Takeda Pharmaceutical by 10.7% in the second quarter. GAMMA Investing LLC now owns 13,837 shares of the company’s stock valued at $222,000 after acquiring an additional 1,338 shares during the last quarter. Versant Capital Management Inc lifted its stake in Takeda Pharmaceutical by 10.8% in the second quarter. Versant Capital Management Inc now owns 42,686 shares of the company’s stock valued at $684,000 after acquiring an additional 4,169 shares during the last quarter. Parallel Advisors LLC grew its position in shares of Takeda Pharmaceutical by 10.5% in the 1st quarter. Parallel Advisors LLC now owns 24,651 shares of the company’s stock valued at $457,000 after acquiring an additional 2,343 shares during the period. Finally, Glenmede Trust Co. NA grew its position in shares of Takeda Pharmaceutical by 9.6% in the 1st quarter. Glenmede Trust Co. NA now owns 30,205 shares of the company’s stock valued at $559,000 after acquiring an additional 2,640 shares during the period. 9.17% of the stock is owned by institutional investors.

Key Stories Impacting Takeda Pharmaceutical

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Insiders continued to hold substantial positions after the transactions, suggesting the sales do not necessarily reflect a loss of confidence in Takeda’s business or outlook. The filings state that the shares were sold to cover tax withholding obligations related to vested equity awards. SEC insider filing
• Neutral Sentiment: Analyst sentiment remains mixed: ratings include two Buys, one Hold and one Sell, resulting in an overall “Hold” consensus. Recent institutional buying has also provided some support, but those purchases were relatively small compared with Takeda’s market capitalization. Takeda stock analysis
• Negative Sentiment: Multiple senior executives and insiders sold a combined 399,? shares at an average price of $17.10. CEO Julie So-Young Kim sold 89,090 shares, Andrew Stewart Plump sold 165,393 shares and General Counsel Natalie Anne Marie Furney sold 30,868 shares. Other insiders also reduced their holdings by approximately 5.9% to 17.8%, which could weigh on investor sentiment despite the tax-related explanation. Takeda insider sales report

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.